A potentially game-changing Alzheimer’s therapy is to undergo clinical trials in America.

Pre-clinical studies carried out by M3 Biotechnology, headquartered in Seattle, of its NDX-1017 drug, showed it could ‘stop or slow’ the progression of the disease.

“Current drugs on the market for Alzheimer’s patients offer only symptomatic relief, whereas we anticipate NDX-1017 will slow, halt and potentially restore lost function. The pre-clinical studies suggest we are on the right path, and we are excited to advance a much-needed brain regenerative therapy to alleviate the suffering of millions afflicted by the disease, and their families, around the world,” said M3 CEO Leen Kawas.

Email this to someoneShare on FacebookTweet about this on TwitterShare on Google+Share on LinkedInShare on StumbleUponPin on Pinterest